B

Reasoning: The new therapy does not change how many new cases of metastatic melanoma arise (incidence), but by prolonging patients’ survival it lengthens the average duration of disease, thereby increasing the number of people living with the cancer at any moment (prevalence = incidence × average duration) [Alho, 1992, PMID: 1637981].